ArticleActas espanolas de psiquiatria2026
Emotional and Behavioural Problems Including Anxiety and Depressive Symptoms Across Tanner Stages in Girls With Central Precocious Puberty: A Retrospective Clinical Study.
Article in Actas espanolas de psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo examine the Tanner stage-specific patterns of psychological and behavioural problems in girls with central precocious puberty (CPP) and to identify clinical predictors of clinically significant psychological impairment.
methodsThis retrospective cross-sectional study included 116 girls with CPP treated between January 2020 and December 2024. Clinical data were extracted from electronic medical records. Pubertal development was classified by breast Tanner staging into stage II (n = 32), stage III (n = 42) and stages IV-V (n = 42). Psychological outcomes were evaluated using the age-standardised Child Behavior Checklist (CBCL) T-scores. For participants aged ≥7 years, depressive and anxiety symptoms were assessed using the Children's Depression Inventory and the Screen for Child Anxiety Related Emotional Disorders. The independent predictors of clinically significant psychological problems were identified through logistic regression analysis, defined as CBCL Total Problems T-score of ≥64, and model performance was assessed using receiver operating characteristic curve analysis.
resultsThe mean CBCL Total Problems T-score was 58.6 ± 12.4, and 50 girls (43.1%) had clinically significant psychological problems. Psychological burden increased across Tanner stages. The CBCL Total T-scores were 52.4 ± 10.8 in stage II, 58.6 ± 11.6 in stage III and 65.8 ± 13.2 in stages IV-V (p < 0.001). The prevalence of clinically significant problems increased from 21.9% to 40.5% and 61.9% (p = 0.002). Internalising symptoms showed a stronger stage-related pattern than externalising symptoms. Early age at onset was associated with increased symptom severity (r = -0.385, p < 0.001). Multivariable analysis identified Tanner stages IV-V versus stage II (odds ratio [OR] = 2.94, 95% confidence interval [CI]: 1.44-5.99, p = 0.003), younger age at onset (OR = 0.72, 95% CI: 0.55-0.94, p = 0.016), higher peak luteinising hormone (LH) (OR = 1.45, 95% CI: 1.08-1.95, p = 0.014) and family history of early puberty (OR = 2.18, 95% CI: 1.26-3.77, p = 0.005) as independent predictors. The prediction model showed good discrimination (area under the curve = 0.812, 95% CI: 0.738-0.886).
conclusionsGirls with CPP experience substantial psychological burden, and risk increases with pubertal stage. Advanced Tanner stage, earlier pubertal onset, increase in peak LH and family history are indicators for enhanced psychological monitoring and support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.